|Bid||1.60 x 1000|
|Ask||1.80 x 2200|
|Day's Range||1.6900 - 1.8000|
|52 Week Range||1.4500 - 3.6000|
|Beta (3Y Monthly)||0.09|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 14, 2019 - Mar 18, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||9.00|
Financing Led by Abingworth; Andrew Sinclair, Partner, to Join Soleno’s Board Funding to Support Ongoing Phase III Clinical Program (DESTINY PWS) for DCCR in Prader-Willi.
In 2014 Anish Bhatnagar was appointed CEO of Soleno Therapeutics, Inc. (NASDAQ:SLNO). This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. Next, we'll Read More...
Soleno Therapeutics, Inc. (SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that clinical data from a Phase II study (PC025) of diazoxide choline controlled release (DCCR) investigating the effects of DCCR treatment on hyperphagia and fat loss in patients with Prader-Willi Syndrome (PWS) were delivered today in a poster presentation at the Obesity Society Meeting 2018, taking place this week in Nashville, TN. “While the hallmark characteristic of PWS is hyperphagia, PWS patients also experience ectopic accumulation of body fat, obesity and associated cardiometabolic complications, which is the leading cause of death of PWS patients,” said Anish Bhatnagar, M.D., Chief Executive Officer of Soleno.
The latest earnings update Soleno Therapeutics Inc’s (NASDAQ:SLNO) released in December 2017 suggested that losses became smaller relative to the prrior year’s level – great news for investors Below isRead More...
When Soleno Therapeutics Inc (NASDAQ:SLNO) released its most recent earnings update (30 September 2017), I compared it against two factor: its historical earnings track record, and the performance of itsRead More...
Soleno Therapeutics Inc’s (NASDAQ:SLNO): Soleno Therapeutics, Inc. focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. With the latest financial year loss of -US$10.39MRead More...